Liquid Suspension of Zonisamide Available for Oral Administration to Treat Partial Seizures in Adults

Zonisamide (Zonisade; Azurity Pharmaceuticals, Woburn, MA), an antiseizure medication for treatment of partial seizures, will become available as a liquid suspension (100 mg/5 mL) in retail pharmacies on October 17, 2022. The oral liquid formulation of zonisamide is FDA- approved and is the only alternative formulation to solid oral doses of zonisamide.
 
“Despite many advancements in epilepsy research and management over the last decade, unmet treatment needs continue to remain for epilepsy patients suffering from partial-onset seizures,” said Evan Scullin, MD, chief medical officer of Azurity Pharmaceuticals. “With the introduction of zonisamide, epilepsy patients age 16 years or more with partial seizures living in the US now have access to an oral liquid zonisamide formulation that may aid in the administration and management of this complex brain disorder.”

“The epilepsy patient and provider community’s treatment needs are widespread and unique, requiring continuous advancements in treatment,” said Michael C. Smith, MD, director, Rush Epilepsy Center, and professor, Department of Neurological Sciences, Rush University Medical Center. “The oral liquid formulation offered with zonisade may help the significant number of patients who have difficulty swallowing and could offer prescribing physicians greater flexibility in meeting patient needs.”